Canopy Growth (CGC) Other Non-Current Liabilities (2017 - 2026)
Canopy Growth (CGC) reported Other Non-Current Liabilities of $27.3 million for Q1 2026, up 7.81% on a YoY basis from $25.3 million in Q1 2025, and up 244.31% sequentially from $7.9 million in Q4 2025.
Canopy Growth (CGC) Other Non-Current Liabilities (2017 - 2026) Analysis & Trends
Canopy Growth (CGC) has 10 years of Other Non-Current Liabilities data on file, last reported at $27.3 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Liabilities rose 7.81% year-over-year to $27.3 million; the trailing twelve-month figure through Mar 2026 stood at $27.3 million (up 7.81% YoY), and the FY2026 full-year result was $27.3 million, up 7.81% from the prior year.
- Other Non-Current Liabilities advanced to $27.3 million in Q1 2026, from $7.9 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $73.4 million in Q2 2023 to a low of $529821.7 in Q3 2022.
- A 5-year average of $25.4 million and a median of $22.6 million in 2022 frame the typical range for Other Non-Current Liabilities.
- Across the five-year window, Other Non-Current Liabilities slumped 99.37% in 2022 and surged 2808.56% in 2023, its largest moves.
- Tracing CGC's Other Non-Current Liabilities over 5 years: stood at $29.4 million in 2022, then plunged by 76.19% to $7.0 million in 2023, then soared by 242.51% to $24.0 million in 2024, then sank by 66.97% to $7.9 million in 2025, then soared by 244.31% to $27.3 million in 2026.
- Business Quant data shows CGC's Other Non-Current Liabilities at $27.3 million in Q1 2026, $7.9 million in Q4 2025, and $11.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Canopy Growth | 197.77 Mn | -68.15 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.25 Mn |
| Dec 31, 2025 | 7.92 Mn |
| Sep 30, 2025 | 11.13 Mn |
| Jun 30, 2025 | 8.65 Mn |
| Mar 31, 2025 | 25.28 Mn |
| Dec 31, 2024 | 23.97 Mn |
| Sep 30, 2024 | 33.25 Mn |
| Jun 30, 2024 | 48.11 Mn |
| Mar 31, 2024 | 53.29 Mn |
| Dec 31, 2023 | 7.00 Mn |
| Sep 30, 2023 | 15.41 Mn |
| Jun 30, 2023 | 73.36 Mn |
| Dec 31, 2022 | 29.39 Mn |
| Sep 30, 2022 | 529,821.66 |
| Jun 30, 2022 | 20.86 Mn |
| Mar 31, 2022 | 21.25 Mn |
| Dec 31, 2021 | 155.19 Mn |
| Sep 30, 2021 | 84.06 Mn |
| Jun 30, 2021 | 88.71 Mn |
| Mar 31, 2021 | 486.37 Mn |